Australia Vaccines Market By Technology Type (Inactivated Vaccines, Toxoid Vaccines, Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Others) , By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rota

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,098	90 Pages	Allied Market Research	November, 2024	ALMR19510656

Best Price Guarantee
Price	from $3,098
Length	90 Pages
Publisher	Allied Market Research
Published Date	November, 2024
SKU	ALMR19510656

Australia Vaccines Market By Technology Type (Inactivated Vaccines, Toxoid Vaccines, Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Others) , By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP) , Polio, Hepatitis, Other Indications) By End User (Pediatric, Adults, Travelers) : Opportunity Analysis and Industry Forecast, 2024-2033

Australia Vaccines Market

The Australia vaccines market was valued at $0.6 billion in 2023 and is projected to reach $1.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

A vaccine is a biological preparation injected into individuals to gain immunity against infectious, life-threatening diseases. It is composed of the whole or some components of viruses, bacteria, or toxins responsible for causing the disease. The working principle of vaccines involves triggering of immune response in the body, without causing the disease. The key elements of a vaccine include antigens, adjuvants, stabilizers, and preservatives. There are different types of vaccines, each with a different approach to stimulating the immune system. These include inactivated vaccines, subunit vaccines, live attenuated vaccines, toxoid vaccines, and DNA or mRNA vaccines.

Rise in initiatives such as the National Immunization Program by the government to provide free vaccines for a wide range of diseases is a key driver of the Australia vaccines market. In addition, increase in awareness among individuals regarding the importance of vaccination to prevent the outbreak of infectious diseases augments the development of the market. An ongoing development anticipated to become a prominent trend in the coming years is the formation of compound vaccines. These vaccines contain different antigens from bacteria, viruses, and other microorganisms, resulting in the development of one formulation that offers protection from multiple diseases.

However, the stringent regulatory standard regarding the development of new vaccines to ensure safety & efficacy results in delayed approvals and multiple clinical trials, which hampers the development of the market. Moreover, supply chain disruptions and distribution challenges in remote or rural areas limit the accessibility of vaccines, restraining the market development notably. Contrarily, rise in government expenditure and increase in the establishment of agreements with different international suppliers to maintain a constant supply of vaccines are projected to present lucrative opportunities for the Australia vaccines market. For instance, the Department of Health and Aged Care of the Australian Government released an article stating that they have invested approximately $18 billion in Australia’s vaccine and COVID-19 treatment supply as part of the COVID-19 health response.

Segment Review

The Australia vaccines market is segmented into technology type, indication, and end user. On the basis of technology type, the market is divided into inactivated vaccines, toxoid vaccines, recombinant & conjugate vaccines, live attenuated vaccines, and others. Depending on indication, the market is categorized into pneumococcal disease; influenza; human papilloma virus; meningococcal disease; rotavirus; varicella; measles, mumps, & rubella; diphtheria, pertussis, & tetanus (DTP); polio; hepatitis; and other indications. As per end user, it is classified into pediatric, adults, and travelers.

Key Findings

On the basis of technology type, the recombinant & conjugate vaccines segment was the highest shareholder in 2023.

Depending on indication, the human papilloma virus segment held a notable share of the market in 2023.

As per end user, the pediatric segment dominated the market in 2023.

Competition Analysis

The leading players operating in the Australia vaccines market include Merck & Co., Inc., Sanofi, AstraZeneca, Pfizer, CSL, Emergent BioSolutions, Vaxine Pty Ltd., Biocelect, BioDiem, and GSK plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Key Market Segments

By Technology Type

Inactivated Vaccines
Toxoid Vaccines
Recombinant and Conjugate Vaccines
Live Attenuated Vaccines
Others

By Indication

Pneumococcal Disease
Influenza
Human Papilloma Virus
Meningococcal Disease
Rotavirus
Varicella
Measles, Mumps, and Rubella
Diphtheria, Pertussis, and Tetanus (DTP)
Polio
Hepatitis
Other Indications

By End User

Pediatric
Adults
Travelers

Key Market Players

Merck & Co., Inc.
Sanofi
AstraZeneca
Pfizer
CSL
Emergent BioSolutions
Vaxine Pty Ltd.
Biocelect
BioDiem
GSK plc.

CHAPTER 1: INTRODUCTION: 1.1. Report Description; 1.2. Key Market Segments; 1.3. Key Benefits; 1.4. Research Methodology; 1.4.1. Primary Research; 1.4.2. Secondary Research; 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY: 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE: 3.1. Market Definition and Scope; 3.2. Key Findings; 3.2.1. Top Investment Pockets; 3.2.2. Top Winning Strategies; 3.3. Porter's Five Forces Analysis; 3.3.1. Bargaining Power of Suppliers; 3.3.2. Threat of New Entrants; 3.3.3. Threat of Substitutes; 3.3.4. Competitive Rivalry; 3.3.5. Bargaining Power among Buyers; 3.4. Market Dynamics; 3.4.1. Drivers; 3.4.2. Restraints; 3.4.3. Opportunities
CHAPTER 4: AUSTRALIA VACCINES MARKET, BY TECHNOLOGY TYPE: 4.1. Market Overview; 4.1.1 Market Size and Forecast, By Technology Type; 4.2. Inactivated Vaccines; 4.2.1. Key Market Trends, Growth Factors and Opportunities; 4.3. Toxoid Vaccines; 4.3.1. Key Market Trends, Growth Factors and Opportunities; 4.4. Recombinant And Conjugate Vaccines; 4.4.1. Key Market Trends, Growth Factors and Opportunities; 4.5. Live Attenuated Vaccines; 4.5.1. Key Market Trends, Growth Factors and Opportunities; 4.6. Others; 4.6.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 5: AUSTRALIA VACCINES MARKET, BY INDICATION: 5.1. Market Overview; 5.1.1 Market Size and Forecast, By Indication; 5.2. Pneumococcal Disease; 5.2.1. Key Market Trends, Growth Factors and Opportunities; 5.3. Influenza; 5.3.1. Key Market Trends, Growth Factors and Opportunities; 5.4. Human Papilloma Virus; 5.4.1. Key Market Trends, Growth Factors and Opportunities; 5.5. Meningococcal Disease; 5.5.1. Key Market Trends, Growth Factors and Opportunities; 5.6. Rotavirus; 5.6.1. Key Market Trends, Growth Factors and Opportunities; 5.7. Varicella; 5.7.1. Key Market Trends, Growth Factors and Opportunities; 5.8. Measles, Mumps, And Rubella; 5.8.1. Key Market Trends, Growth Factors and Opportunities; 5.9. Diphtheria, Pertussis, And Tetanus (DTP); 5.9.1. Key Market Trends, Growth Factors and Opportunities; 5.10. Polio; 5.10.1. Key Market Trends, Growth Factors and Opportunities; 5.11. Hepatitis; 5.11.1. Key Market Trends, Growth Factors and Opportunities; 5.12. Other Indications; 5.12.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 6: AUSTRALIA VACCINES MARKET, BY END USER: 6.1. Market Overview; 6.1.1 Market Size and Forecast, By End User; 6.2. Pediatric; 6.2.1. Key Market Trends, Growth Factors and Opportunities; 6.3. Adults; 6.3.1. Key Market Trends, Growth Factors and Opportunities; 6.4. Travelers; 6.4.1. Key Market Trends, Growth Factors and Opportunities
CHAPTER 7: COMPETITIVE LANDSCAPE: 7.1. Introduction; 7.2. Top Winning Strategies; 7.3. Product Mapping Of Top 10 Player; 7.4. Competitive Dashboard; 7.5. Competitive Heatmap; 7.6. Top Player Positioning,2023
CHAPTER 8: COMPANY PROFILES: 8.1. Merck And Co., Inc.; 8.1.1. Company Overview; 8.1.2. Key Executives; 8.1.3. Company Snapshot; 8.1.4. Operating Business Segments; 8.1.5. Product Portfolio; 8.1.6. Business Performance; 8.1.7. Key Strategic Moves and Developments; 8.2. Sanofi; 8.2.1. Company Overview; 8.2.2. Key Executives; 8.2.3. Company Snapshot; 8.2.4. Operating Business Segments; 8.2.5. Product Portfolio; 8.2.6. Business Performance; 8.2.7. Key Strategic Moves and Developments; 8.3. AstraZeneca; 8.3.1. Company Overview; 8.3.2. Key Executives; 8.3.3. Company Snapshot; 8.3.4. Operating Business Segments; 8.3.5. Product Portfolio; 8.3.6. Business Performance; 8.3.7. Key Strategic Moves and Developments; 8.4. Pfizer; 8.4.1. Company Overview; 8.4.2. Key Executives; 8.4.3. Company Snapshot; 8.4.4. Operating Business Segments; 8.4.5. Product Portfolio; 8.4.6. Business Performance; 8.4.7. Key Strategic Moves and Developments; 8.5. CSL; 8.5.1. Company Overview; 8.5.2. Key Executives; 8.5.3. Company Snapshot; 8.5.4. Operating Business Segments; 8.5.5. Product Portfolio; 8.5.6. Business Performance; 8.5.7. Key Strategic Moves and Developments; 8.6. Emergent BioSolutions; 8.6.1. Company Overview; 8.6.2. Key Executives; 8.6.3. Company Snapshot; 8.6.4. Operating Business Segments; 8.6.5. Product Portfolio; 8.6.6. Business Performance; 8.6.7. Key Strategic Moves and Developments; 8.7. Vaxine Pty Ltd.; 8.7.1. Company Overview; 8.7.2. Key Executives; 8.7.3. Company Snapshot; 8.7.4. Operating Business Segments; 8.7.5. Product Portfolio; 8.7.6. Business Performance; 8.7.7. Key Strategic Moves and Developments; 8.8. Biocelect; 8.8.1. Company Overview; 8.8.2. Key Executives; 8.8.3. Company Snapshot; 8.8.4. Operating Business Segments; 8.8.5. Product Portfolio; 8.8.6. Business Performance; 8.8.7. Key Strategic Moves and Developments; 8.9. BioDiem; 8.9.1. Company Overview; 8.9.2. Key Executives; 8.9.3. Company Snapshot; 8.9.4. Operating Business Segments; 8.9.5. Product Portfolio; 8.9.6. Business Performance; 8.9.7. Key Strategic Moves and Developments; 8.10. GSK Plc.; 8.10.1. Company Overview; 8.10.2. Key Executives; 8.10.3. Company Snapshot; 8.10.4. Operating Business Segments; 8.10.5. Product Portfolio; 8.10.6. Business Performance; 8.10.7. Key Strategic Moves and Developments; LIST OF TABLES; TABLE 1. AUSTRALIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION); TABLE 2. AUSTRALIA VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION); TABLE 3. AUSTRALIA VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 4. MERCK AND CO., INC.: KEY EXECUTIVES; TABLE 5. MERCK AND CO., INC.: COMPANY SNAPSHOT; TABLE 6. MERCK AND CO., INC.: OPERATING SEGMENTS; TABLE 7. MERCK AND CO., INC.: PRODUCT PORTFOLIO; TABLE 8. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 9. SANOFI: KEY EXECUTIVES; TABLE 10. SANOFI: COMPANY SNAPSHOT; TABLE 11. SANOFI: OPERATING SEGMENTS; TABLE 12. SANOFI: PRODUCT PORTFOLIO; TABLE 13. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 14. ASTRAZENECA: KEY EXECUTIVES; TABLE 15. ASTRAZENECA: COMPANY SNAPSHOT; TABLE 16. ASTRAZENECA: OPERATING SEGMENTS; TABLE 17. ASTRAZENECA: PRODUCT PORTFOLIO; TABLE 18. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 19. PFIZER: KEY EXECUTIVES; TABLE 20. PFIZER: COMPANY SNAPSHOT; TABLE 21. PFIZER: OPERATING SEGMENTS; TABLE 22. PFIZER: PRODUCT PORTFOLIO; TABLE 23. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 24. CSL: KEY EXECUTIVES; TABLE 25. CSL: COMPANY SNAPSHOT; TABLE 26. CSL: OPERATING SEGMENTS; TABLE 27. CSL: PRODUCT PORTFOLIO; TABLE 28. CSL: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 29. EMERGENT BIOSOLUTIONS: KEY EXECUTIVES; TABLE 30. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT; TABLE 31. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS; TABLE 32. EMERGENT BIOSOLUTIONS: PRODUCT PORTFOLIO; TABLE 33. EMERGENT BIOSOLUTIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 34. VAXINE PTY LTD.: KEY EXECUTIVES; TABLE 35. VAXINE PTY LTD.: COMPANY SNAPSHOT; TABLE 36. VAXINE PTY LTD.: OPERATING SEGMENTS; TABLE 37. VAXINE PTY LTD.: PRODUCT PORTFOLIO; TABLE 38. VAXINE PTY LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 39. BIOCELECT: KEY EXECUTIVES; TABLE 40. BIOCELECT: COMPANY SNAPSHOT; TABLE 41. BIOCELECT: OPERATING SEGMENTS; TABLE 42. BIOCELECT: PRODUCT PORTFOLIO; TABLE 43. BIOCELECT: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 44. BIODIEM: KEY EXECUTIVES; TABLE 45. BIODIEM: COMPANY SNAPSHOT; TABLE 46. BIODIEM: OPERATING SEGMENTS; TABLE 47. BIODIEM: PRODUCT PORTFOLIO; TABLE 48. BIODIEM: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 49. GSK PLC.: KEY EXECUTIVES; TABLE 50. GSK PLC.: COMPANY SNAPSHOT; TABLE 51. GSK PLC.: OPERATING SEGMENTS; TABLE 52. GSK PLC.: PRODUCT PORTFOLIO; TABLE 53. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; LIST OF FIGURES; FIGURE 1. AUSTRALIA VACCINES MARKET,2024 - 2033; FIGURE 2. SEGMENTATION OF AUSTRALIA VACCINES MARKET,2024 - 2033; FIGURE 3. TOP INVESTMENT POCKET IN AUSTRALIA VACCINES MARKET,2024 - 2033; FIGURE 4. MODERATE BARGAINING POWER OF BUYERS; FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS; FIGURE 6. MODERATE THREAT OF NEW ENTRANTS; FIGURE 7. LOW THREAT OF SUBSTITUTION; FIGURE 8. HIGH COMPETITIVE RIVALRY; FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: AUSTRALIA VACCINES MARKET; FIGURE 10. AUSTRALIA VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION); FIGURE 11. AUSTRALIA VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION); FIGURE 12. AUSTRALIA VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION); FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*; FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*; FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*; FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 17. COMPETITIVE DASHBOARD; FIGURE 18. COMPETITIVE HEATMAP: AUSTRALIA VACCINES MARKET; FIGURE 19. TOP PLAYER POSITIONING,2023; FIGURE 20. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION); FIGURE 21. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 22. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 23. SANOFI: NET SALES, 2021-2023 ($BILLION); FIGURE 24. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 25. SANOFI: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 26. ASTRAZENECA: NET SALES, 2021-2023 ($BILLION); FIGURE 27. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 28. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 29. PFIZER: NET SALES, 2021-2023 ($BILLION); FIGURE 30. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 31. PFIZER: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 32. CSL: NET SALES, 2021-2023 ($BILLION); FIGURE 33. CSL: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 34. CSL: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 35. EMERGENT BIOSOLUTIONS: NET SALES, 2021-2023 ($BILLION); FIGURE 36. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 37. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 38. VAXINE PTY LTD.: NET SALES, 2021-2023 ($BILLION); FIGURE 39. VAXINE PTY LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 40. VAXINE PTY LTD.: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 41. BIOCELECT: NET SALES, 2021-2023 ($BILLION); FIGURE 42. BIOCELECT: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 43. BIOCELECT: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 44. BIODIEM: NET SALES, 2021-2023 ($BILLION); FIGURE 45. BIODIEM: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 46. BIODIEM: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 47. GSK PLC.: NET SALES, 2021-2023 ($BILLION); FIGURE 48. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 49. GSK PLC.: REVENUE SHARE, BY REGION, 2023 (%)
LIST OF TABLES: TABLE 1. AUSTRALIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION); TABLE 2. AUSTRALIA VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION); TABLE 3. AUSTRALIA VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 4. MERCK AND CO., INC.: KEY EXECUTIVES; TABLE 5. MERCK AND CO., INC.: COMPANY SNAPSHOT; TABLE 6. MERCK AND CO., INC.: OPERATING SEGMENTS; TABLE 7. MERCK AND CO., INC.: PRODUCT PORTFOLIO; TABLE 8. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 9. SANOFI: KEY EXECUTIVES; TABLE 10. SANOFI: COMPANY SNAPSHOT; TABLE 11. SANOFI: OPERATING SEGMENTS; TABLE 12. SANOFI: PRODUCT PORTFOLIO; TABLE 13. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 14. ASTRAZENECA: KEY EXECUTIVES; TABLE 15. ASTRAZENECA: COMPANY SNAPSHOT; TABLE 16. ASTRAZENECA: OPERATING SEGMENTS; TABLE 17. ASTRAZENECA: PRODUCT PORTFOLIO; TABLE 18. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 19. PFIZER: KEY EXECUTIVES; TABLE 20. PFIZER: COMPANY SNAPSHOT; TABLE 21. PFIZER: OPERATING SEGMENTS; TABLE 22. PFIZER: PRODUCT PORTFOLIO; TABLE 23. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 24. CSL: KEY EXECUTIVES; TABLE 25. CSL: COMPANY SNAPSHOT; TABLE 26. CSL: OPERATING SEGMENTS; TABLE 27. CSL: PRODUCT PORTFOLIO; TABLE 28. CSL: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 29. EMERGENT BIOSOLUTIONS: KEY EXECUTIVES; TABLE 30. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT; TABLE 31. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS; TABLE 32. EMERGENT BIOSOLUTIONS: PRODUCT PORTFOLIO; TABLE 33. EMERGENT BIOSOLUTIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 34. VAXINE PTY LTD.: KEY EXECUTIVES; TABLE 35. VAXINE PTY LTD.: COMPANY SNAPSHOT; TABLE 36. VAXINE PTY LTD.: OPERATING SEGMENTS; TABLE 37. VAXINE PTY LTD.: PRODUCT PORTFOLIO; TABLE 38. VAXINE PTY LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 39. BIOCELECT: KEY EXECUTIVES; TABLE 40. BIOCELECT: COMPANY SNAPSHOT; TABLE 41. BIOCELECT: OPERATING SEGMENTS; TABLE 42. BIOCELECT: PRODUCT PORTFOLIO; TABLE 43. BIOCELECT: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 44. BIODIEM: KEY EXECUTIVES; TABLE 45. BIODIEM: COMPANY SNAPSHOT; TABLE 46. BIODIEM: OPERATING SEGMENTS; TABLE 47. BIODIEM: PRODUCT PORTFOLIO; TABLE 48. BIODIEM: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 49. GSK PLC.: KEY EXECUTIVES; TABLE 50. GSK PLC.: COMPANY SNAPSHOT; TABLE 51. GSK PLC.: OPERATING SEGMENTS; TABLE 52. GSK PLC.: PRODUCT PORTFOLIO; TABLE 53. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES: FIGURE 1. AUSTRALIA VACCINES MARKET,2024 - 2033; FIGURE 2. SEGMENTATION OF AUSTRALIA VACCINES MARKET,2024 - 2033; FIGURE 3. TOP INVESTMENT POCKET IN AUSTRALIA VACCINES MARKET,2024 - 2033; FIGURE 4. MODERATE BARGAINING POWER OF BUYERS; FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS; FIGURE 6. MODERATE THREAT OF NEW ENTRANTS; FIGURE 7. LOW THREAT OF SUBSTITUTION; FIGURE 8. HIGH COMPETITIVE RIVALRY; FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: AUSTRALIA VACCINES MARKET; FIGURE 10. AUSTRALIA VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION); FIGURE 11. AUSTRALIA VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION); FIGURE 12. AUSTRALIA VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION); FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*; FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*; FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*; FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 17. COMPETITIVE DASHBOARD; FIGURE 18. COMPETITIVE HEATMAP: AUSTRALIA VACCINES MARKET; FIGURE 19. TOP PLAYER POSITIONING,2023; FIGURE 20. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION); FIGURE 21. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 22. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 23. SANOFI: NET SALES, 2021-2023 ($BILLION); FIGURE 24. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 25. SANOFI: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 26. ASTRAZENECA: NET SALES, 2021-2023 ($BILLION); FIGURE 27. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 28. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 29. PFIZER: NET SALES, 2021-2023 ($BILLION); FIGURE 30. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 31. PFIZER: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 32. CSL: NET SALES, 2021-2023 ($BILLION); FIGURE 33. CSL: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 34. CSL: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 35. EMERGENT BIOSOLUTIONS: NET SALES, 2021-2023 ($BILLION); FIGURE 36. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 37. EMERGENT BIOSOLUTIONS: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 38. VAXINE PTY LTD.: NET SALES, 2021-2023 ($BILLION); FIGURE 39. VAXINE PTY LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 40. VAXINE PTY LTD.: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 41. BIOCELECT: NET SALES, 2021-2023 ($BILLION); FIGURE 42. BIOCELECT: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 43. BIOCELECT: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 44. BIODIEM: NET SALES, 2021-2023 ($BILLION); FIGURE 45. BIODIEM: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 46. BIODIEM: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 47. GSK PLC.: NET SALES, 2021-2023 ($BILLION); FIGURE 48. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 49. GSK PLC.: REVENUE SHARE, BY REGION, 2023 (%)